Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source

Source document· February 9, 2026

Life Sciences Analytics Market Advances to US$ 23.17 Billion by 2033 on AI-Driven Drug Discovery and Cloud Platforms Says Astute Analytica

View original at finance.yahoo.com

Life Sciences Analytics Market Advances to US$ 23.17 Billion by 2033 on AI-Driven Drug Discovery and Cloud Platforms Says Astute Analytica AstuteAnalytica India Pvt…

Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

North America's leadership in life sciences analytics stems from strong research infrastructure, extensive clinical trials, and a concentration of top-tier academic institutions
80% confidence
Growth is fueled by the adoption of advanced analytics platforms, AI-driven modules, and cloud-based solutions that optimize drug discovery, clinical trials, pharmacovigilance, and precision medicine
80% confidence
Leading players such as Roche, Johnson & Johnson, AstraZeneca, and Merck are investing heavily in specialized analytics tools and dedicated data teams to accelerate real-time decision-making, improve patient stratification, and enhance treatment outcomes
80% confidence
The global life sciences analytics market was valued at 11.10 billion in 2024 and is expected to reach US$ 23.17 billion by 2033, growing at a CAGR of 8.52% from 2025 to 2033
80% confidence

Data points we hold from this source

Merck & Co., Inc. · module count	3 ai_modules
AstraZeneca AB · solution count	9 cloud_solutions
Sanofi · dashboard count	3 unified_dashboards